Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase EARLY_PHASE1 1

Status

Unknown 2Recruiting 1

Sponsor Class

OTHER_GOV 1OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Carcinoma, Non-Small-Cell Lung 387Breast Neoplasms 368Colorectal Neoplasms 242Stomach Neoplasms 221Carcinoma, Hepatocellular 155Lung Neoplasms 125Neoplasms 122Pancreatic Neoplasms 112Prostatic Neoplasms 101Rectal Neoplasms 98Neoplasm Metastasis 98Recurrence 94Ovarian Neoplasms 92Nasopharyngeal Carcinoma 89Esophageal Neoplasms 84Esophageal Squamous Cell Carcinoma 83Lymphoma, Large B-Cell, Diffuse 80Melanoma 78Lymphoma 72Small Cell Lung Carcinoma 71Sarcoma 71Leukemia, Myeloid, Acute 71Uterine Cervical Neoplasms 70Brain Neoplasms 70Squamous Cell Carcinoma of Head and Neck 67Multiple Myeloma 67Head and Neck Neoplasms 67Carcinoma, Renal Cell 65Triple Negative Breast Neoplasms 63Colonic Neoplasms 55

Interventions

Erlotinib Hydrochloride 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Unknown × EGFR Positive Non-small Cell Lung Cancer × Clear all
NCT03126799 2022-04-06

AvaTa

National Cancer Center, Korea

Phase 2 Unknown
128 enrolled
Thoracic

EGFR Positive Non-small Cell Lung Cancer

NCT03382795 2021-07-15

Retreatment With Epidermal Growth Factor Receptor(EGFR) Tyrosine Kinase Inhibitor in EGFR Mutation Positive Patients

Korea University Guro Hospital

Phase 2 Unknown
63 enrolled
Thoracic

EGFR Positive Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡